CXCR4 and clear cell renal carcinoma: For example, phosphoglycerate kinase 1 (PGK1) plays a role in the development of renal clear cell carcinoma and resistance to sorafenib by activating the C-X-C motif chemokine receptor 4 (CXCR4)/ERK pathway, thereby accelerating glycolysis.37